ArbLens Weekly: Best 5 Merger Arbitrage Deals by Risk-Reward
The widest spread isn't always the best trade. This week we rank the five deals that offer the most compelling balance of upside, deal certainty, downside protection, and timeline — the factors that actually determine whether a merger arb position makes money.
Last week's issue ranked deals by raw spread — the simple gap between the current stock price and the offer price. That's useful as a starting point. But experienced arb investors know the spread is only half the equation. A 37% spread that requires an opaque Israeli government decision with no fixed timeline is a fundamentally different proposition than a 14% spread that could close in eight weeks.
This week, we're ranking by risk-reward: the combination of spread magnitude, deal certainty (how many closing conditions remain), downside protection (termination fees, financing commitments), and timeline (annualized return if the deal closes on schedule). Three of our top five didn't even make the top-six-by-spread list last week. Two that did — ZIM and BLD — drop out entirely, replaced by deals that are less dramatic but more likely to make you money.
Issue #1 vs Issue #2 — What Changed
Last week (Issue #1) ranked by raw spread: ZIM 36.9%, BLD 26.0%, WBD 14.9%, NSC 13.8%, BHF 11.9%, GSAT 9.8%. Spread is a clean, objective metric — but it doesn't tell you whether that spread is compensation for a realistic regulatory timeline or for genuine deal-break risk. This week we add three dimensions: how many closing conditions remain (deal certainty), what happens if the deal fails (downside protection), and how long your capital is locked up (annualized return). The result is a different list — and arguably a more actionable one.
WBD was #3 by spread last week. It's #1 by risk-reward this week — and the reason arrived today. Paramount announced on May 20 that it intends to close the deal by July 15, 2026 — less than eight weeks from now, significantly ahead of the previous Q3 2026 target. That transforms the math: 14.4% in eight weeks annualizes to roughly 95%.
The deal certainty stack is strong: 99%+ shareholder approval (April 23), DOJ HSR clearance (February 19), fully committed financing ($47B equity from Ellison/RedBird, $54B debt). What remains is a single binary catalyst: the UK CMA Phase 1 decision, expected within 40 working days of the April launch — meaning late May or early June. CMA clearance at Phase 1 would remove the last obstacle. A Phase 2 referral would extend the hold by 6-9 months, but the $0.25/share quarterly ticking fee kicks in after September 30, compensating for the delay. The $7B termination fee payable by Paramount if regulators block makes walk-away risk minimal.
The risk-reward case for BHF is simple: there is almost no deal-break risk. This is the cleanest structural setup in the tracker. Shareholder vote passed (February 2026). No antitrust concerns — it's an insurance acquisition, not a horizontal merger. No competing bids. No cross-border complexity. No financing contingency. Aquarian Capital is a specialised insurance PE firm that has done this exact type of deal before.
The only variable is when, not if. Multi-state insurance regulatory approvals — particularly the New York DFS — follow no fixed timetable. DFS reviews typically take 12-18 months. BHF reported a Q1 2026 net loss of $792M (derivative mark-to-market, non-cash) — this doesn't affect deal economics but regulators may ask capital adequacy questions that add procedural time. H2 2026 close is management's target; Q1 2027 is the market's base case. Either way, 12% for a near-certain outcome is solid patient-capital deployment.
A 4.1% spread looks modest — until you realise this is the largest leveraged buyout in history ($55B) with only a single remaining approval. HSR antitrust clearance is done. Shareholders approved in December 2025. $20B in committed debt financing from JPMorgan. The consortium extended its bond tender offers to June 15 — a signal they expect to close soon. EA posted record FY26 net bookings of $8B but declined to host an earnings call, typical of a company about to go private.
The sole remaining gating factor is CFIUS — the Committee on Foreign Investment in the United States. Saudi Arabia's Public Investment Fund is the lead equity investor, which triggers national security review. But PIF already held a 9.9% stake pre-deal (approved by CFIUS at the time), and this is a financial acquisition of a gaming company, not a defense contractor. The outside date is September 28, 2026. At a 4-month horizon, 4.1% annualizes to roughly 12%. The $1B reverse break fee protects EA shareholders if regulators block. A Canadian union is pushing for federal scrutiny of EA's Canadian operations — a background risk to monitor but unlikely to derail.
GSAT was #6 by spread last week and moves up to #4 on risk-reward because the deal has something no other deal in the tracker has: an acquirer with effectively infinite financial resources and existential strategic motivation. Amazon is buying globally harmonised satellite spectrum that SpaceX cannot replicate — this is the regulatory asset that enables Amazon Leo to compete on direct-to-device. No shareholder vote was needed (Thermo Funding's 57.6% majority approved by written consent April 13). No financing risk ($86B cash on Amazon's balance sheet). The Apple dependency was neutralised simultaneously with a long-term connectivity agreement.
The spread compensates for a multi-jurisdictional regulatory process: HSR, FCC, and international clearances (EU, Canada, Brazil, Australia). The operational milestone risk — satellite launch commissioning — could reduce the per-share consideration by up to $110M if targets are missed. But Amazon has never walked away from a strategic infrastructure acquisition. The outside date is April 2027 with extensions to 2028. This is a long hold, but the deal-break probability is the lowest of any deal in the top 10 by spread.
IMXI is the prototypical "low-spread, high-certainty, short-duration" arb trade — the type that doesn't make headlines but compounds capital efficiently. Western Union acquiring International Money Express for $16/share cash, a straightforward remittance industry consolidation play. Shareholders already approved (December 2025). Regulatory review underway with a Q2 2026 close target — roughly six weeks from today.
At a June 30 close, 4.6% in six weeks annualizes to roughly 40%. The deal is small ($500M), meaning regulatory review is lighter than mega-deals. No material antitrust concerns — the remittance market is fragmented with Wise, Remitly, Ria, and dozens of regional players. No financing contingency. This is the kind of position that experienced arb investors use to keep capital productive between larger positions — a high-probability short-duration trade that frees up capital quickly for redeployment.
The Deals That Dropped Out
ZIM (37% spread) has the widest spread in the tracker — but the Israeli Golden Share decision has no fixed timeline, no procedural milestones to track, and the Sakal competing bid introduces legal ambiguity. The spread is pricing genuine binary risk, not just regulatory delay. High upside, but the risk-reward ratio favours conviction investors over systematic arb allocators.
BLD (27% spread) is the newest deal in the top six — announced April 19, only one month ago. HSR hasn't been filed. The S-4 hasn't been filed. Neither shareholder vote has been scheduled. The regulatory clock hasn't even started. And the 55% QXO stock proration means you're partially making a bet on Brad Jacobs' stock, not just on deal closure. Give this one another month to develop before it earns a risk-reward ranking.
NSC (13% spread) is a high-quality deal with 99% shareholder support and a $2.5B termination fee — but the STB process is 15+ months minimum from a complete filing, which was only just submitted on April 30. At a mid-2027 earliest close, 13% annualizes to roughly 8%. The capital lockup is the longest of any deal in the tracker. Solid for long-duration portfolios, but the annualized return doesn't compete with WBD, EA, or IMXI on a risk-reward basis.
Live spreads, spread history charts, and full deal analysis — including background, investment thesis, key risks, and catalysts — for every deal in the tracker.
View Live Tracker →Get the next issue delivered to your inbox — spreads, deal updates, and what to watch every week.